These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 31626255)
1. Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. McDaid WJ; Greene MK; Johnston MC; Pollheimer E; Smyth P; McLaughlin K; Van Schaeybroeck S; Straubinger RM; Longley DB; Scott CJ Nanoscale; 2019 Nov; 11(42):20261-20273. PubMed ID: 31626255 [TBL] [Abstract][Full Text] [Related]
2. Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. Greene MK; Chen T; Robinson E; Straubinger NL; Minx C; Chan DKW; Wang J; Burrows JF; Van Schaeybroeck S; Baker JR; Caddick S; Longley DB; Mager DE; Straubinger RM; Chudasama V; Scott CJ Br J Cancer; 2020 Nov; 123(10):1502-1512. PubMed ID: 32913288 [TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208 [TBL] [Abstract][Full Text] [Related]
4. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer. Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695 [TBL] [Abstract][Full Text] [Related]
5. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198 [TBL] [Abstract][Full Text] [Related]
6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938 [TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts. Sreeranganathan M; Uthaman S; Sarmento B; Mohan CG; Park IK; Jayakumar R Int J Nanomedicine; 2017; 12():7165-7182. PubMed ID: 29033568 [TBL] [Abstract][Full Text] [Related]
8. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy. Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780 [TBL] [Abstract][Full Text] [Related]
10. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166 [TBL] [Abstract][Full Text] [Related]
11. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920 [TBL] [Abstract][Full Text] [Related]
12. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422 [TBL] [Abstract][Full Text] [Related]
14. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485 [TBL] [Abstract][Full Text] [Related]
15. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer. Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320 [TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455 [TBL] [Abstract][Full Text] [Related]
17. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483 [TBL] [Abstract][Full Text] [Related]
18. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805 [TBL] [Abstract][Full Text] [Related]
19. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]